Search the Newsreel

Citizens reiterates Market Outperform on DBV Technologies stock, $55 target

Citizens has reaffirmed its Market Outperform rating and $55 price target for DBV Technologies. The reiteration follows DBV's pipeline update and second-quarter financial results, which included a delay in the Viaskin Peanut BLA submission to the third quarter to incorporate FDA feedback. Despite a …

DBV Technologies (DBV) Registration filing Summary

This article summarizes DBV Technologies' registration filing, highlighting its focus as a clinical-stage biopharmaceutical company developing Viaskin for food allergies, with Viaskin Peanut as its lead product candidate. The company's financial performance shows ongoing net losses and cash runway concerns, despite recent financing efforts …

DBV Technologies Has Sufficient Funding to Support Ops for at Least 12 Mos Into 3Q 2027

DBV Technologies has announced that it possesses sufficient funding to cover its operational expenses and planned capital expenditures for at least the next 12 months, extending into the third quarter of 2027. This financial stability provides a clear runway for the company's ongoing activities …

DBV Technologies 2Q Loss/Shr 12c

This article reports that DBV Technologies had a loss per share of 12 cents in the second quarter. No additional financial details or context are provided in the current content.

DBV Technologies reports $98.0M half‑year net loss, $174.9M cash at June 30, 2026

DBV Technologies reported a net loss of $98.0 million for the first half of 2026, including a $50.4 million loss in Q2, with cash and cash equivalents of $174.9 million as of June 30, 2026, expected to fund operations into Q3 2027. The company …

DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update

DBV Technologies announced its second quarter and half-year 2026 financial results, highlighting continued progress towards the Biologics License Application (BLA) submission for its Viaskin Peanut Patch in children aged 4-7, now anticipated in Q3 2026. The company reported $174.9 million in cash and cash …

DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report

DBV Technologies announced the filing of its Half-Year Report for the semester ending June 30, 2026, with the French market authority, AMF. The report is available on the Company's website (Investors/Financial Information section) and the AMF website (in French only). DBV Technologies is a …

DBV Technologies (DBV) Q1 2025 earnings summary

DBV Technologies reported a Q1 2025 net loss of $27.1 million, a slight improvement year-over-year, with total operating expenses decreasing by 9%. The company is focused on the regulatory approval of its Viaskin Peanut patch, with pivotal trial results expected in Q4 2025 and …

DBV Technologies (NASDAQ:DBVT) Releases Earnings Results, Misses Estimates By $0.48 EPS

Diversify Wealth Management LLC Invests $1.29 Million in DBV Technologies S.A. $DBVT

DBV Technologies Q2 Earnings Call Highlights

DBV Technologies (DBVT) Gains 2.55% as Shares Approach Key Resistance Level - Corrective Wave

DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?

DBV Technologies Surges 4.05% as Stock Nears Key Resistance Level (DBVT) - Earnings Beat Stocks

DBV Technologies Shareholders Approve Governance and Capital Measures

DBV Technologies (DBVT) Upgraded to Buy: What Does It Mean for the Stock?

DBV Technologies (ENXTPA:DBV) Quarterly Loss Of US$33.2m Reinforces Bearish Profitability Narratives

Why DBV Technologies (ENXTPA:DBV) Is Up 21.7% After Extending Its VIASKIN Peanut Funding Runway

What date does DBV Technologies's (DBVT) report Earnings - Earnings Calendar & Announcement

DBV Technologies (DBVT) Earnings Date and Reports 2026

DBV Technologies (DBVT) Stock Price, News & Analysis

DBV Technologies - DBVT - Stock Price Today